Trexquant Investment LP Buys 10,090 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Trexquant Investment LP raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 25.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 49,297 shares of the specialty pharmaceutical company's stock after acquiring an additional 10,090 shares during the period. Trexquant Investment LP owned approximately 0.08% of Jazz Pharmaceuticals worth $6,071,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. CIBC Asset Management Inc increased its holdings in Jazz Pharmaceuticals by 5.2% in the fourth quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company's stock valued at $243,000 after purchasing an additional 97 shares during the last quarter. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after purchasing an additional 129 shares during the period. Jones Financial Companies Lllp increased its stake in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 130 shares in the last quarter. Waterfront Wealth Inc. raised its holdings in Jazz Pharmaceuticals by 1.4% in the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares during the period. Finally, Ellsworth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 0.4% during the fourth quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company's stock worth $4,675,000 after purchasing an additional 149 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on JAZZ. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $145.00 to $179.00 in a report on Friday, March 7th. Morgan Stanley reiterated an "overweight" rating and issued a $183.00 price objective (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, Royal Bank of Canada dropped their price objective on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $187.71.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This represents a 7.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares of the company's stock, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,736 shares of company stock valued at $4,023,305. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $11.99 during midday trading on Thursday, hitting $98.13. 844,870 shares of the company's stock were exchanged, compared to its average volume of 770,803. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $5.96 billion, a PE ratio of 13.77, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company's 50 day moving average price is $130.49 and its 200 day moving average price is $122.78.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.